Learn more about the medicines in Gilead’s pipeline—medicines that demonstrate the potential to advance the treatment of life-threatening diseases including liver disease… Experts warn that the designation, reserved for treating “rare diseases,” could block supplies of the antiviral medication from generic drug manufacturers and provide a lucrative windfall for Gilead Sciences, which maintains close ties with President Donald Trump’s “The Orphan Drug Act is for a rare disease, and this is about as an extreme opposite of a rare disease you can possibly dream up,” said James Love, director of Knowledge Ecology International, a watchdog on pharmaceutical patent abuse.“They’re talking about potentially half the population of the United States,” said Love, adding that “it’s absurd that this would happen in the middle of an epidemic when everything is in short supply.”The 1983 Orphan Drug Act gives special inducements to pharmaceutical companies to make products that treat rare diseases.
Science & Medicine
As of May 20, one-third of sponsors were switching to virtual or decentralized models, according to the Tufts Center for the Study of Drug Development (CSDD). WASHINGTON — Facing public criticism, the maker of a promising coronavirus drug said Wednesday it will waive a special regulatory designation that could have allowed it to block competition and boost profits for its treatment.The Food and Drug Administration granted the company’s request for the designation on Monday, noting that COVID-19 qualified as a rare disease under U.S. rules, since fewer than 200,000 Americans are infected.But experts and public advocates blasted Gilead for seeking the status.“COVID-19 is anything but a rare disease,” stated a letter sent to the company earlier Wednesday by more than 50 consumer and patient advocacy groups.
“They’re going to be very aggressive in how they go after this.”Portland’s new district attorney said he wouldn’t prosecute most protesters. Other pharmaceutical firms, Today, Gilead abruptly announced that it would no longer provide emergency access to remdesivir, telling the New York Times that “The special orphan designation, which can also be granted to drugs when there is little reasonable expectation that a company will recoup its research costs, was given to remdesivir despite hefty support by the government for the development of the drug.Gilead Sciences’ remdesivir was developed with at least $79 million in U.S. government funding, according to a The U.S. National Institute Allergies and Infectious Diseases continued providing significant taxpayer funding to subsidize the development of remdesivir. As of Wednesday, cases in the U.S. topped 61,000.Gilead said in a statement Wednesday afternoon that it asked the FDA to rescind the orphan drug designation and that the company “recognizes the urgent public health needs posed by the COVID-19 pandemic.”Currently, there are no FDA-approved drugs, vaccines or specific treatments for the coronavirus. COVID-19 & Rare Diseases Find expert recommendations and services, including those provided by European Reference Networks, concerning COVID-19 and rare diseases, in different languages. Annual Health Care Conference, an investor event for major pharmaceutical and health care corporations. Coronavirus Treatment Developed by Gilead Sciences Granted “Rare Disease” Status, Potentially Limiting Affordability. As of press time, there were more than 40,000 confirmed cases of Covid-19 in the U.S, and some 366,000 worldwide.The distinction could severely limit supply of remdesivir by granting Gilead Sciences exclusive protection over the drug and complete control of its price. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.The pharma giant reported that LY-CoV555, developed in Unlock this story instantly and join 90,100+ biopharma pros reading Endpoints daily — and it's free.